Gentherm Inc: Form 10-Q for the period ended Mar 31, 2020
Filed with the SEC on May 7, 2020 and accepted by EDGAR at May 7, 2020, 17:08 ET.
Management's discussion and analysis
As filed, 42,290 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Forward-Looking Statements
This Quarterly Report on Form 10-Q (this “Report”) contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent our goals, beliefs, plans and expectations about our prospects for the future and other future events, such as the impact of the COVID-19 pandemic on our financial results, liquidity, and business as well as the global economy, the amount of borrowing availability under the Amended Credit Agreement and the sufficiency of our cash balances and cash generated from operating, investing and financing activities for our future liquidity and capital resource needs, our ability to finance sufficient working capital, our ability to execute our strategic plan and Manufacturing Footprint Rationalization restructuring plan. Reference is made in particular to forward-looking statements included in this “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations”. Such statements may be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “believe”, “estimate”, “anticipate”, “intend”, “continue”, or similar terms, variations of such terms or the negative of such terms. The forward-looking statements included in this Report are made as of the date hereof or as of the date specified herein and are based on management’s current expectations and beliefs. Such statements are subject to a number of assumptions, risks, uncertainties and other factors, which are set forth in “Item 1A. Risk Factors” and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2019, Part II “Item 1A. Risk Factors” in this Report and subsequent reports filed with the Securities and Exchange Commission, and which could cause actual results to differ materially from that described in the forward-looking statements. In addition, such forward-looking statements do not include the potential impact of any business combinations, acquisitions, divestitures, strategic investments and other significant transactions that may be completed after the date hereof, each of which may present material risks to the Company’s business and financial results. Except as required by law, we expressly disclaim any obligation or undertaking to update any forward-looking statements to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
The following discussion and analysis should be read in conjunction with, and is qualified in its entirety by, our consolidated condensed financial statements and related notes thereto included elsewhere in this Report and our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2019.
Overview
Gentherm Incorporated is a global developer and marketer of innovative thermal management technologies for a broad range of heating and cooling and temperature control applications. Unless the context otherwise requires, the terms “Gentherm”, “Company”, “we”, “us” and “our” used herein refer to Gentherm Incorporated and its consolidated subsidiaries. Our products provide solutions for automotive passenger climate comfort and convenience, battery thermal management and cell connecting systems, as well as patient temperature management within the health care industry. Our automotive products can be found in the vehicles of nearly all major automotive manufacturers operating in North America and Europe, and several major automotive manufacturers in Asia. We operate in locations aligned with our major customers’ product strategies to provide locally enhanced design, integration and production capabilities. The Company is also developing a number of new technologies and products that will help enable improvements to existing products and to create new product applications for existing and new markets.
Our sales are driven by the number of vehicles produced by the automotive manufacturers, which is ultimately dependent on consumer demand for automotive vehicles, and our content per vehicle. Historically, new vehicle demand has been driven by macro-economic and other factors, such as interest rates, manufacturer and dealer sales incentives, fuel prices, consumer confidence, employment levels, income growth trends and government and tax incentives. Economic volatility or weakness, as well as geopolitical factors, in North America, Europe or Asia, could result in a significant reduction in automotive sales and production by our customers, which would have an adverse effect on our business, results of operations and financial condition. While our diversified automotive OEM customer base and geographic revenue base, along with our flexible cost structure, have well positioned us to withstand the impact of industry downturns, including the current impact of the COVID-19 pandemic, and benefit from industry upturns in the ordinary course, shifts in the mix of global automotive production to higher cost regions or to vehicles with less content could adversely impact our profitability. In addition, we may be adversely impacted by volatility, weakness or slow growth in markets for hybrid electric vehicles specifically.
Recent Trends and Economic Conditions
The COVID-19 pandemic has significantly disrupted global economic activity, including in the automotive market. As a result of the global spread of the COVID-19 pandemic, light vehicle production volumes have declined across all regions. According to the forecasting firm IHS Markit, global light vehicle production was 17.6 million units in the first quarter of 2020, down from 22.9 million units in the first quarter of 2019, a decline of 23.0%. In the first quarter of 2020, customer plants in North America and Europe were closed beginning in the second half of March due to the pandemic. This resulted in temporary, partial closures of several of our manufacturing facilities in the North America and Europe by the end of March. In Asia, customer plants, as well as our plants, were closed for several weeks in February, and operated at reduced volumes in March. The impact of the outbreak has expanded beyond China and its surrounding regions where the outbreak initially began in December 2019 and has transitioned to an event impacting the entire global economy and automotive market. IHS Markit forecasted light vehicle production volumes for full-year 2020 is 69.3 million units, a decline of 22.0% from full-year 2019.
With respect to our key markets, actual light vehicle production volumes in North America for the first quarter of 2020 were 3.8 million units compared to 4.2 million units in the first quarter of 2019, a decrease of 9.5%, and light vehicle production volumes in Europe were 4.6 million units for the first quarter of 2020 compared to 5.7 million units in the first quarter of 2019, a decrease of 19.3%. Actual light vehicle production volumes in Japan/Korea were 3.0 million units in the first quarter of 2020 compared to 3.3 million units in the first quarter of 2019, a decrease of 9.1%. The largest light vehicle production volume decline was in China, with 3.2 million units in the first quarter of 2020 compared to 6.0 million units in the first quarter of 2019, a decrease of 46.7%.
While the COVID-19 pandemic materially adversely affected our results of operations in the first quarter, the full extent of the impact may not be fully reflected in our results of operations until future periods, and we believe that the adverse impact of the COVID-19 pandemic has worsened in the second quarter. Such impact will be materially adverse to our business and results of operations, and may be materially adverse to our financial condition, cash flows, liquidity and stock price. In light of the substantial economic and financial impact of the COVID-19 pandemic and resulting uncertainties, the Company has taken significant actions to address its liquidity position. In March 2020, the Company borrowed an additional $169 million under its revolving credit facility to increase its cash position and provide additional financial flexibility. In addition, the Company has been prudently addressing its day-to-day operations, including reducing expenses, inventory levels and capital spending and deferring 2020 base salaries generally for salaried employees. See “—Liquidity and Capital Resources” below for additional information.
New Business Awards
We believe that innovation is an important element to gaining market acceptance of our products and strengthening our market position. During the first quarter of 2020, we secured an estimated $120 million of automotive new business awards, which represents the estimated future lifetime product revenues for all automotive customers. Automotive new business awards represent the aggregate projected lifetime revenue of new awards provided by customers to Gentherm in the applicable period, with the value based on the price and volume projections received from each customer as of the award date. Although automotive new business awards are not firm customer orders, we believe that new business awards are an indicator of future revenue. New business awards are not projections of revenue or future business as of March 31, 2020, the date of this Report or any other date. Customer projections regularly change over time and we do not update our calculation of any new business award after the date initially communicated. Automotive new business awards in the first quarter 2020 also do not reflect, in particular, the impact of the COVID-19 pandemic on future business. Revenues resulting from automotive new business awards also are subject to additional risks and uncertainties as described under “Forward-Looking Statements” above.
Divestitures
Divestiture of CSZ-IC
On February 1, 2019, the Company completed the divestiture of CSZ-IC and the former Cincinnati Sub-Zero headquarters facility to Weiss Technik North America, Inc. for total cash proceeds of $47.5 million. In connection with the sale, Gentherm entered into an operating lease agreement for a portion of the office and manufacturing building space purchased by Weiss Technik North America, Inc. The Company recognized a $5.0 million pre-tax gain on the sale of CSZ-IC during the three months ended March 31, 2019. $2.5 million of cash proceeds remain in an escrow account pending resolution of a claim.
Divestiture of GPT
On October 1, 2019, the Company completed the divesture of GPT for a nominal amount.
Acquisitions
Acquisition of Stihler Electronic GmbH (“Stihler”)
On April 1, 2019, Gentherm acquired Stihler, a leading developer and manufacturer of patient and blood temperature management systems, for a purchase price of $15.5 million, net of cash acquired and including $0.7 million of contingent consideration to be paid upon achievement of a milestone that must be completed by September 2020. In addition, the purchase agreement includes a contingent payment of $0.7 million to be paid if the selling shareholder remains employed by Stihler through December 2020, which will be recorded as a component of selling, general and administrative expenses ratably over the service period. The results of operations of Stihler are reported within the Company’s Industrial segment from the date of acquisition.
Restructuring
Manufacturing Footprint Rationalization
On September 23, 2019, the Company committed to a restructuring plan to improve the Company’s manufacturing productivity and rationalize its footprint. Under this plan, the Company will relocate and consolidate certain existing automotive manufacturing and, as a result, reduce the number of plants by two. During the three months ended March 31, 2020, the Company recognized expense of $0.2 million for employee separation costs that will be paid pursuant to the terms of statutory requirements of the affected locations. Additionally, the Company recognized $0.2 million of accelerated depreciation during such period. The Company has recorded approximately $7.4 million of restructuring expenses since the inception of this program.
See Note 4, “Restructuring”, to our consolidated condensed financial statements included in this Report for information about our restructuring activities.
GPT and CSZ-IC Restructuring
During 2019, the Company completed its plan to eliminate non-core areas of investment through the divestitures of its environmental test equipment business, Cincinnati Sub-Zero industrial chamber business (“CSZ-IC”) and its remote power generation systems business, Gentherm Global Power Technologies (“GPT”). In addition, we launched a plan to optimize our manufacturing footprint and took additional actions to reduce costs through purchasing excellence and additional restructuring activities focused on reductions of selling, general and administrative expense. During the three months ended March 31, 2019, the Company recognized $0.3 million of employee separation costs, and $0.8 million of other related costs, related to the marketing of GPT and CSZ-IC, in restructuring expenses.
See Note 4, “Restructuring”, to our consolidated condensed financial statements included in this Report for information about our restructuring activities.
Other Restructuring Activities
As part of the Company’s continued efforts to optimize its cost structure, the Company has undertaken several discrete restructuring actions. During the three months ended March 31, 2020 and 2019, the Company recognized $3.1 million and $0.4 million of employee separation costs, respectively, and $0.2 million and less than $0.1 million of other related costs, respectively. In addition, during the three months ended March 31, 2019, the Company recognized $0.4 million of asset impairment loss. These restructuring expenses were primarily associated with restructuring actions focused on the rotation of our manufacturing footprint to lower cost locations and the reduction of global overhead costs. These discrete restructuring actions are expected to approximate the total cumulative costs for those actions. The Company will continue to explore opportunities to improve its future profitability and competitiveness. These actions may result in the recognition of additional restructuring charges that could be material
See Note 4, “Restructuring”, to our consolidated condensed financial statements included in this Report for information about our restructuring activities.
Stock Repurchase Program
In December 2016, the Board of Directors authorized a three-year, $100.0 million stock repurchase program. In June 2018, our Board of Directors authorized an increase in the stock repurchase program to $300.0 million and extended the stock repurchase program until December 2020. In March 2020, the Company suspended its share repurchase program in order to preserve liquidity. However, repurchases under the stock repurchase program may resume at management’s discretion and may be made, from time to time, in amounts and at prices the Company deems appropriate, subject to market conditions, applicable legal requirements, debt covenants and other considerations. During the three months ended March 31, 2020, we repurchased approximately $9.1 million of shares and have a remaining repurchase authorization of approximately $74.2 million.
See Note 15, “Equity”, to our consolidated condensed financial statements included in this Report for information about our stock repurchase program.
Reportable Segments
The Company has two reportable segments for financial reporting purposes: Automotive and Industrial. See Note 6, “Segment Reporting”, to the consolidated condensed financial statements included in this Report for a description of our reportable segments as well as their proportional contribution to the Company’s reported product revenues and operating income. The financial information used by our chief operating decision maker to assess operating performance and allocate resources is based on these reportable segments.
Results of Operations First Quarter 2020 Compared with First Quarter 2019
The results of operations for the three months ended March 31, 2020 and March 31, 2019, in thousands, were as follows:
| Three Months Ended March 31, 2020 | 2019 | Favorable / (Unfavorable) | |
|---|---|---|---|
| Product revenues | $228,613 | $257,921 | $(29,308) |
| Cost of sales | 162,546 | 182,614 | 20,068 |
| Gross margin | 66,067 | 75,307 | (9,240) |
| Operating expenses: | |||
| Net research and development expenses | 17,760 | 18,897 | 1,137 |
| Selling, general and administrative expenses | 25,840 | 32,651 | 6,811 |
| Restructuring expenses | 3,766 | 1,914 | (1,852) |
| Total operating expenses | 47,366 | 53,462 | 6,096 |
| Operating income | 18,701 | 21,845 | (3,144) |
| Interest expense, net | (748) | (1,368) | 620 |
| Foreign currency (loss) gain | (938) | 203 | (1,141) |
| Gain on sale of business | — | 4,970 | (4,970) |
| Impairment loss | — | (10,484) | 10,484 |
| Other income | 264 | 143 | 121 |
| Earnings before income tax | 17,279 | 15,309 | 1,970 |
| Income tax expense | 5,406 | 6,895 | 1,489 |
| Net income | $11,873 | $8,414 | $3,459 |
27
Product revenues by product category, in thousands, for the three months ended March 31, 2020 and March 30, 2019, were as follows:
| Three Months Ended March 31, 2020 | 2019 | % Change | |
|---|---|---|---|
| Climate Control Seats (CCS) | $82,528 | $94,354 | (12.5%) |
| Seat Heaters | 64,532 | 73,920 | (12.7%) |
| Automotive Cables | 22,140 | 23,749 | (6.8%) |
| Steering Wheel Heaters | 19,235 | 16,970 | 13.3% |
| Battery Thermal Management (BTM) | 11,209 | 10,745 | 4.3% |
| Electronics | 10,376 | 12,852 | (19.3%) |
| Other Automotive | 6,452 | 9,767 | (33.9%) |
| Subtotal Automotive | $216,472 | $242,357 | (10.7%) |
| Medical | 12,141 | 8,187 | 48.3% |
| GPT | — | 3,959 | (100.0%) |
| CSZ-IC | — | 3,418 | (100.0%) |
| Subtotal Industrial | $12,141 | $15,564 | (22.0%) |
| Total Company | $228,613 | $257,921 | (11.4%) |
Product Revenues
Below is a summary of our product revenues, in thousands, for the three months ended March 31, 2020 and March 31, 2019:
| Three Months Ended March 31, 2020 | 2019 | Favorable / (Unfavorable) | Variance Due To: Volume | FX | Pricing/Other | Total | |
|---|---|---|---|---|---|---|---|
| Product revenues | $228,613 | $257,921 | $(29,308) | $(17,193) | $(3,149) | $(8,966) | $(29,308) |
Product revenues for the three months ended March 31, 2020 decreased 11.4% as compared to the three months ended March 31, 2019. The decrease in product revenues is primarily due to unfavorable volumes in our Automotive segment, with an estimated $28 million of such decrease driven by the COVID-19 pandemic. Product revenues were also negatively impacted by foreign currency impacts, primarily related to the Euro, Korean Won and Chinese Renminbi. The decrease in product revenues included in Variance Due To Pricing/Other above is primarily attributable to the divestitures of CSZ-IC on February 1, 2019 and GPT on October 1, 2019, as well as decreases in customer pricing, partially offset by the acquisition of Stihler on April 1, 2019. The decrease in product revenues included in Variance Due To Pricing/Other above was also offset by an increase in product revenue of approximately $1 million in our Industrial segment primarily due to increased demand for our Blanketrol® solutions to support temperature management of COVID-19 patients.
Cost of Sales
Below is a summary of our cost of sales and gross margin, in thousands, for the three months ended March 31, 2020 and March 31, 2019:
| Three Months Ended March 31, 2020 | 2019 | Favorable / (Unfavorable) | Variance Due To: Volume | Operational Performance | FX | Other | Total | |
|---|---|---|---|---|---|---|---|---|
| Cost of sales | $162,546 | $182,614 | $20,068 | $9,726 | $6,164 | $1,754 | $2,424 | $20,068 |
| Gross margin | 66,067 | 75,307 | (9,240) | $(7,467) | $684 | $(1,395) | $(1,062) | $(9,240) |
| Gross margin - Percentage of product revenues | 28.9% | 29.2% |
Cost of sales for the three months ended March 31, 2020 decreased 11.0% as compared to the three months ended March 31, 2019. The decrease in cost of sales is due to the volume decreases of $17.6 million for our Automotive segment primarily related to the impact of the COVID-19 pandemic, operational performance improvements and favorable foreign currency impacts, primarily attributable to the Euro, Mexican Peso, Ukrainian Hryvnia and Chinese Renminbi. The operational performance improvements are primarily attributable to decrease in material costs. The decrease in cost of sales is also due to the following items included in Variance Due to Other above:
- $5.2 million of decrease attributable to divested businesses (CSZ-IC and GPT);
- $1.2 million of increase due to higher labor costs in Mexico, Ukraine and Macedonia, partially offset by lower labor costs in China; and
- $2.0 million of increase attributable to Medical, including the impact of the acquisition of Stihler on April 1, 2019.
Net Research and Development Expenses
Below is a summary of our net research and development expenses, in thousands, for the three months ended March 31, 2020 and March 31, 2019:
| Three Months Ended March 31, 2020 | 2019 | Favorable / (Unfavorable) | |
|---|---|---|---|
| Research and development expenses | $20,537 | $22,608 | $2,071 |
| Reimbursed research and development expenses | $(2,777) | $(3,711) | $(934) |
| Net research and development expenses | $17,760 | $18,897 | $1,137 |
| Percentage of product revenues | 7.8% | 7.3% |
Net research and development expenses for the three months ended March 31, 2020 decreased 6.0% as compared to the three months ended March 31, 2019. The decrease in net research and development expenses is primarily related to reduced project-related spending.
Selling, General and Administrative Expenses
Below is a summary of our selling, general and administrative expenses, in thousands, for the three months ended March 31, 2020 and March 31, 2019:
| Three Months Ended March 31, 2020 | 2019 | Favorable / (Unfavorable) | |
|---|---|---|---|
| Selling, general and administrative expenses | $25,840 | $32,651 | $6,811 |
| Percentage of product revenues | 11.3% | 12.7% |
Selling, general and administrative expenses for the three months ended March 31, 2020 decreased 20.9% as compared to the three months ended March 31, 2019. The decrease in selling, general and administrative expenses is primarily related to the impacts of divested businesses (CSZ-IC and GPT), lower stock compensation expense as a result of mark to market revaluation of stock appreciation rights during the three months ended March 31, 2020, as well as the absence of CFO transition costs in the three months ended March 31, 2020.
Restructuring Expenses
Below is a summary of our restructuring expenses, in thousands, for the three months ended March 31, 2020 and March 31, 2019:
| Three Months Ended March 31, 2020 | 2019 | Favorable / (Unfavorable) | |
|---|---|---|---|
| Restructuring expenses | $3,766 | $1,914 | $(1,852) |
Restructuring expenses primarily relate to the Manufacturing Footprint Rationalization restructuring program and other discrete restructuring actions focused on the rotation of our manufacturing footprint to lower cost locations and the reduction of global overhead expenses. During the three months ended March 31, 2020, the Company recognized expenses of $3.3 million for employee separation costs, $0.2 million of accelerated depreciation and $0.2 million of other related costs. During the three months ended March 31, 2019, the Company recognized expenses of $0.6 million for employee separation costs, $0.4 million of asset impairment charges and $0.8 million of other related costs.
See Note 4, “Restructuring” of the consolidated condensed financial statements included in this Report for additional information.
Interest Expense
Below is a summary of our interest expense, in thousands, for the three months ended March 31, 2020 and March 31, 2019:
| Three Months Ended March 31, 2020 | 2019 | Favorable / (Unfavorable) | |
|---|---|---|---|
| Interest expense, net | $(748) | $(1,368) | $620 |
See Note 11, “Debt” of the consolidated condensed financial statements included in this Report for additional information.
Foreign Currency (Loss) Gain
Below is a summary of our foreign currency (loss) gain, in thousands, for the three months ended March 31, 2020 and March 31, 2019:
| Three Months Ended March 31, 2020 | 2019 | Favorable / (Unfavorable) | |
|---|---|---|---|
| Foreign currency (loss) gain | $(938) | $203 | $(1,141) |
Foreign currency loss for the three months ended March 31, 2020 included net realized foreign currency loss of $0.2 million and net unrealized foreign currency loss of $0.8 million.
Foreign currency gain for the three months ended March 31, 2019 included net realized foreign currency loss of $0.8 million and net unrealized foreign currency gain of $1.0 million.
Gain on Sale of Business
Below is a summary of our gain on sale of business, in thousands, for the three months ended March 31, 2020 and March 31, 2019:
| Three Months Ended March 31, 2020 | 2019 | Favorable / (Unfavorable) | |
|---|---|---|---|
| Gain on sale of business | $— | $4,970 | $(4,970) |
On February 1, 2019, as part of the Company’s Fit-for-Growth initiative to eliminate investments in non-core businesses, we completed the sale of CSZ-IC to Weiss Technik North America, Inc. The Company recognized a pre-tax gain of $5.0 million on the sale of CSZ-IC during the three months ended March 31, 2019.
Impairment Loss
Below is a summary of our impairment loss, in thousands, for the three months ended March 31, 2020 and March 31, 2019:
| Three Months Ended March 31, 2020 | 2019 | Favorable / (Unfavorable) | |
|---|---|---|---|
| Impairment loss | $— | $(10,484) | $10,484 |
During the three months ended March 31, 2019, the Company recorded an impairment loss of $10.5 million associated with the divestiture of GPT. See Note 3, “Acquisitions and Divestitures” of the consolidated condensed financial statements included in this Report for additional information.
Other income
Below is a summary of our other income, in thousands, for the three months ended March 31, 2020 and March 31, 2019:
| Three Months Ended March 31, 2020 | 2019 | Favorable / (Unfavorable) | |
|---|---|---|---|
| Other income | $264 | $143 | $121 |
The increase in other income is primarily due to an increase in miscellaneous income.
Income Tax Expense
Below is a summary of our income tax expense, in thousands, for the three months ended March 31, 2020 and March 31, 2019:
| Three Months Ended March 31, 2020 | 2019 | Favorable / (Unfavorable) | |
|---|---|---|---|
| Income tax expense | $5,406 | $6,895 | $1,489 |
Income tax expense was $5.4 million for the three months ended March 31, 2020, on earnings before income tax of $17.3 million, representing an effective tax rate of 31.3%. The effective tax rate differed from the U.S. Federal statutory rate of 21% primarily due to the international provisions of the U.S. tax reform, such as global intangible low-tax income (“GILTI”), enacted in December 2017, partly offset by certain intercompany transactions which disproportionately benefited lower tax rate jurisdictions.
Income tax expense was $6.9 million for the three months ended March 31, 2019, on earnings before income tax of $15.3 million, representing an effective tax rate of 45.0%. The pre-tax earnings amount included the non-deductible impairment loss of $10.5 million. Adjusted for the impairment loss, the effective tax rate was 26.7% for the three months ended March 31, 2019. The effective tax rate differed from the U.S. Federal statutory rate of 21% primarily due to the international provisions of the U.S. tax reform, such as GILTI, partly offset by certain intercompany transactions which disproportionately benefited lower tax rate jurisdictions.
Changes in U.S. federal or foreign tax laws and regulations, or their interpretation and application, including those with retroactive effect, could significantly impact our provision for income taxes, the amount of taxes payable, our deferred tax asset and liability balances, and shareholders’ equity. The recently enacted CARES Act, together with earlier issued IRS guidance, provides for deferral of certain taxes. As permitted by the CARES Act, the Company expects to defer the payment of payroll taxes each quarter for the remainder of 2020 to be paid in the fourth quarters of 2021 and 2022. The Company is evaluating other potential tax benefits under the CARES Act and may be impacted by further government tax guidance or relief.
Liquidity and Capital Resources
Cash and Cash Flows
The Company historically has funded its liquidity needs primarily through cash flows from operating activities and equity and debt financings. Prior to the COVID-19 pandemic, we were focused on a capital allocation strategy within our strategic plan that included a targeted debt-to-earnings leverage ratio and using a portion of our cash flow for Common Stock repurchases. As of March 31, 2020, $74.2 million of availability remained under the stock repurchase program.
In light of the significant economic uncertainty and financial impact of the COVID-19 pandemic, the Company has taken significant actions to address its liquidity. First, the Company has been prudently addressing its day-to-day operations, including reducing expenses, inventory levels and capital spending. In addition, effective May 1, 2010, the Company implemented base salary deferrals until December 31, 2020, including a 30-40% deferral at the Executive level and a 20% deferral for other salaried employees, to control expenses and conserve cash. For U.S. employees, the accumulated deferred base salary will generally be paid on or before March 15, 2021 notwithstanding any termination of employment for any reason prior to payment. The Company also revised its non-employee director compensation program for directors elected at the 2020 annual meeting of shareholders, with all compensation being paid in restricted stock for one year. Further, the Company has suspended its stock repurchase program to preserve liquidity.
Also, in March 2020, the Company increased its borrowings under the Amended Credit Agreement by $169.5 million as a safeguard to increase its cash position and provide additional financial flexibility. The proceeds will be used for working capital and for other general corporate purposes permitted by the Amended Credit Agreement. As of March 31, 2020, inclusive of the new borrowings, $225.4 million was outstanding under the Amended Credit Agreement. Based upon consolidated EBITDA for the twelve months ended March 31, 2020, $226.7 remains available for additional borrowings under the Amended Credit Agreement subject to specified conditions that Gentherm currently satisfies. The Company may incur additional significant borrowing in the near term. The determination of additional borrowing amounts will be evaluated based upon the Company’s ongoing performance, the current economic and industry outlook and the desire to provide additional financial flexibility. Future borrowing availability under the Amended Credit Agreement is subject to the Company’s compliance with financial covenants thereunder (including the Consolidated Leverage Ratio). The Company expects its consolidated EBITDA for the trailing 12 months to continue to be significantly reduced as of the end of the second quarter 2020 due to the COVID-19 impact and it may continue to deteriorate thereafter. Therefore, subject to any amendment or waiver of the Consolidated Leverage Ratio from the lenders, the Company expects future borrowing availability will be materially less than the full amount of capacity available under the U.S. Revolving Note. The Company expects that its lenders will agree to an amendment or waiver to increase the borrowing availability if necessary. Based on the Company’s current operating plan and the foregoing actions, management believes cash and cash equivalents at March 31, 2020, together with cash flows from operating activities, and borrowing available under our Amended Credit Agreement, are sufficient to meet operating and capital expenditure needs, and to service debt, for at least the next 12 months. However, as the impact of the COVID-19 pandemic on the economy and our operations evolves, and cash flows from operations decline, we may need to obtain alternative sources of capital, and we may finance additional liquidity needs in the future through one or more equity or debt offerings.
A continued worldwide disruption could materially affect our future access to sources of liquidity, and there can be no assurance that such capital will be available at all or on reasonable terms. The extent to which the COVID-19 pandemic adversely affects our future financial performance will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to, the duration and spread of the pandemic, its severity, the effectiveness of actions to contain the virus or treat its impact and how quickly and to what extent normal economic and operating conditions can resume. Even after the COVID-19 pandemic has subsided, we may continue to experience significant adverse impacts on our business and financial performance for a lengthy period of time as a result of its global economic impact.
The following table represents our cash, cash equivalents and restricted cash, in thousands:
| Three Months Ended March 31, 2020 | 2019 | |
|---|---|---|
| Cash, cash equivalents and restricted cash at beginning of period | $52,948 | $39,620 |
| Cash provided by operating activities | 29,419 | 6,881 |
| Cash (used in) provided by investing activities | (6,338) | 42,378 |
| Cash provided by (used in) financing activities | 149,841 | (47,401) |
| Foreign currency effect on cash and cash equivalents | (426) | (209) |
| Cash, cash equivalents and restricted cash at end of period | $225,444 | $41,269 |
Cash Flows From Operating Activities
We manage our cash, cash equivalents and restricted cash in order to fund operating requirements and preserve liquidity to take advantage of future business opportunities. The following table compares the cash flows from operating activities during the three months ended March 31, 2020 as compared to the three months ended March 31, 2019, in thousands:
| Operating Activities: | Three Months Ended March 31, 2020 | 2019 | Change |
|---|---|---|---|
| Net income | $11,873 | $8,414 | $3,459 |
| Non-cash adjustments to reconcile net income to cash provided by operating activities: | |||
| Depreciation and amortization | 10,406 | 11,052 | (646) |
| Deferred income taxes | 721 | 1,749 | (1,028) |
| Stock based compensation | 1,942 | 1,968 | (26) |
| Defined benefit pension plan income (expense) | 85 | (617) | 702 |
| Allowance for credit losses | 451 | 229 | 222 |
| Loss on sale of property and equipment | 119 | 178 | (59) |
| Operating lease expense | 1,651 | 1,333 | 318 |
| Impairment loss | — | 10,484 | (10,484) |
| Gain on sale of business | — | (4,970) | 4,970 |
| Net income before non-cash adjustments | 27,248 | 29,820 | (2,572) |
| Changes in operating assets and liabilities: | |||
| Accounts receivable | (2,491) | (8,293) | 5,802 |
| Inventory | (404) | (229) | (175) |
| Other assets | (4,805) | (5,553) | 748 |
| Accounts payable | 13,540 | (2,079) | 15,619 |
| Other liabilities | (3,669) | (6,785) | 3,116 |
| Net cash provided by operating activities | $29,419 | $6,881 | $22,538 |
The following table highlights significant differences between the operating cash flows for the three months ended March 31, 2020 and March 31, 2019, respectively, in thousands:
| Net cash provided by operating activities for the three months ended March 31, 2019 | $6,881 |
| Lower net income before changes in operating assets and liabilities | (2,572) |
| Changes in working capital, net | 26,044 |
| Changes in other assets and liabilities | (934) |
| Net cash provided by operating activities for the three months ended March 31, 2020 | $29,419 |
Net cash provided by operating activities before changes in operating assets and liabilities increased during the three months ended March 31, 2020 primarily due to higher net income and lower operating expenses. Additionally, working capital, net provided unfavorable cash flows related to accounts receivable, inventory and other assets and favorable amounts related to accounts payable and other liabilities.
The following table illustrates changes in working capital during the three months ended March 31, 2020, in thousands:
| Working capital at December 31, 2019 | $217,159 |
| Increase in cash, cash equivalents and restricted cash | 174,024 |
| Increase in accounts receivable | 560 |
| Increase in inventory | 555 |
| Decrease in tax receivables, net | (1,896) |
| Increase in other assets | 3,475 |
| Increase in accounts payable | (14,794) |
| Increase in accrued expenses and other liabilities | (139) |
| Foreign currency effect on working capital | (3,207) |
| Working capital at March 31, 2020 | $375,737 |
The following table highlights significant transactions that contributed to the increase in cash, cash equivalents and restricted cash during the three months ended March 31, 2020, in thousands:
| Net cash provided by operating activities | $29,419 |
| Purchases of property and equipment | (3,231) |
| Repayments of debt | (16,111) |
| Borrowings from U.S. Revolving Note | 169,546 |
| Stock repurchases | (9,092) |
| Proceeds from the exercise of Common Stock options | 5,902 |
| Acquisition of intangible assets | (3,141) |
| Proceeds from the sale of property and equipment | 34 |
| Other items | (830) |
| Increase in cash, cash equivalents and restricted cash | $172,496 |
Cash Flows From Investing Activities
Cash used in investing activities was $6.3 million during the three months ended March 31, 2020, primarily reflecting purchases of property and equipment of $3.2 million and the acquisition of intangible assets of $3.1 million.
Cash Flows From Financing Activities
Cash provided by financing activities was $149.8 million during the three months ended March 31, 2020, reflecting additional borrowings on the U.S. Revolving Note totaling $169.5 million partially offset by payments of principal on the U.S. Revolving Note totaling $16.1 million in aggregate. Borrowings under the Amended Credit Agreement mature on June 27, 2024. See Note 11, “Debt” of the consolidated condensed financial statements included in this Report for additional information. Cash was also paid during the three months ended March 31, 2020 for the repurchase of Common Stock totaling $9.1 million and for cancellations of restricted stock awards totaling $0.4 million, partially offset by proceeds from the exercise of Common Stock options totaling $5.9 million.
Critical Accounting Policies
The discussion and analysis of our financial condition and results of operations are based upon our consolidated condensed financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. For discussion of our significant accounting policies, see Note 2, “Summary of Significant Accounting Policies,” to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2019. There have been no significant changes in our critical accounting policies or critical accounting estimates during the first quarter of 2020. We are not presently aware of any events or circumstances arising from the COVID-19 pandemic that would require us to update our estimates, judgments or revise the carrying value of our assets or liabilities. Our estimates may change, however, as new events occur and additional information is obtained. As a result, actual results may differ significantly from our estimates, and any such differences may be material to our financial statements. For information on the impact of recently issued accounting pronouncements, see Note 2, “New Accounting Pronouncements” in the consolidated condensed financial statements included in this Report.
Off-Balance Sheet Arrangements
At March 31, 2020, we do not have any off-balance sheet arrangements that have, or are, in the opinion of management, reasonably likely to have, a current or future material effect on our financial condition or results of operations.
Effects of Inflation
The automotive component supply industry is subject to inflationary pressures with respect to raw materials and labor, which have historically placed operational and financial burdens on the entire supply chain. Accordingly, the Company continues to take actions with its customers and suppliers to mitigate the impact of these inflationary pressures in the future. Actions to mitigate inflationary pressures with customers include collaboration on alternative product designs and material specifications, contractual price escalation clauses and negotiated customer recoveries. Actions to mitigate inflationary pressures with suppliers include aggregation of purchase requirements to achieve optimal volume benefits, negotiation of cost-reductions and identification of more cost competitive suppliers. While these actions are designed to offset the impact of inflationary pressures, the Company cannot provide assurance that it will be successful in fully offsetting increased costs resulting from inflationary pressure.
Market risk
As filed, 5,318 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Our exposure to market risk for changes in interest rates relates primarily to our debt obligations and foreign currency contracts. We have in the past, and may in the future, place our investments in bank certificates of deposits, debt instruments of the U.S. government, and in high-quality corporate issuers.
We are exposed to market risk from changes in foreign currency exchange rates, short-term interest rates and price fluctuations of certain material commodities. Market risks for changes in interest rates relate primarily to our debt obligations under our Amended Credit Agreement. Foreign currency exchange risks are attributable to sales to foreign customers and purchases from foreign suppliers not denominated in a location’s functional currency, foreign plant operations, intercompany indebtedness, intercompany investments and include exposures to the Euro, Mexican Peso, Canadian Dollar, Hungarian Forint, Macedonian Denar, Ukrainian Hryvnia, Japanese Yen, Chinese Renminbi, Korean Won and Vietnamese Dong.
The Company regularly enters into derivative contracts with the objective of managing its financial and operational exposure arising from these risks by offsetting gains and losses on the underlying exposures with gains and losses on the financial instruments used to hedge them. The maximum length of time over which we hedge our exposure to foreign currency exchange risks is one year. We had foreign currency derivative contracts with a notional value of $22.2 million and $14.4 million outstanding at March 31, 2020 and December 31, 2019, respectively.
We do not enter into derivative financial instruments for speculative or trading purposes. Our hedging relationships are formally documented at the inception of the hedge, and hedges must be highly effective in offsetting changes to future cash flows on hedged transactions both at the inception of a hedge and on an ongoing basis to be designated for hedge accounting treatment. For derivative contracts which can be classified as a cash flow hedge, the effective portion of the change in the fair value of the derivative is recorded to accumulated other comprehensive loss in the consolidated condensed balance sheets. When the underlying hedge transaction is realized, the gain or loss included in accumulated other comprehensive loss is recorded in earnings in the consolidated condensed statements of income on the same line as the gain or loss on the hedged item attributable to the hedged risk. We record the ineffective portion of foreign currency hedging instruments, if any, to foreign currency (loss) gain in the consolidated condensed statements of income. Though we continuously monitor the hedging program, derivative positions and hedging strategies, foreign currency forward exchange agreements have not always been designated as hedging instruments for accounting purposes.
The Company uses an income approach to value derivative instruments, analyzing quoted market prices to calculate the forward values and then discounts such forward values to the present value using benchmark rates at commonly quoted intervals for the instrument’s full term.
Information related to the fair values of all derivative instruments in our consolidated condensed balance sheet as of March 31, 2020 is set forth in Note 13, “Financial Instruments” in the consolidated condensed financial statements included in this Report.
Interest Rate Sensitivity
The table presents principal cash flows and related weighted average interest rates by expected maturity dates for each of the Company’s debt obligations. The information is presented in U.S. dollar equivalents, which is the Company’s reporting currency. The instruments actual cash flows are denominated in U.S. dollars ($USD) or Euros (€EUR), as indicated in parentheses.
| Liabilities Long-Term Debt: | Expected Maturity Date 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total | Fair Value |
|---|---|---|---|---|---|---|---|---|
| Variable rate (€EUR) | $— | $— | $— | $— | $42,417 | $— | $42,417 | $42,417 |
| Variable interest rate as of March 31, 2020 | 1.25% | 1.25% | ||||||
| Variable rate ($USD) | $— | $— | $— | $— | $183,000 | $— | $183,000 | $183,000 |
| Variable interest rate as of March 31, 2020 | 2.20% | 2.20% | ||||||
| Fixed rate ($USD) | $2,500 | $2,500 | $2,500 | $1,250 | $— | $— | $8,750 | $9,063 |
| Fixed interest rate | 5.21% | 5.21% | 5.21% | 5.21% | 5.21% |
36
Exchange Rate Sensitivity
The table below provides information about the Company’s foreign currency forward exchange rate agreements that are sensitive to changes in foreign currency exchange rates. The table presents the notional amounts and weighted average exchange rates by expected (contractual) maturity dates for each type of foreign currency forward exchange agreement. These notional amounts generally are used to calculate the contractual payments to be exchanged under the contract.
| Anticipated Transactions and Related Derivatives USD Functional Currency Forward Exchange Agreements: (Receive $MXN / Pay $USD) | Expected Maturity or Transaction Date 2020 | Total | Fair Value |
|---|---|---|---|
| Total contract amount | $22,176 | $22,176 | $(3,553) |
| Average contract rate | 20.29 | 20.29 |
Controls and procedures
As filed, 1,269 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
(a) Evaluation of Disclosure Controls and Procedures
Due to the COVID-19 pandemic, a significant portion of our employees are now working from home, while also under shelter-in-place orders or other restrictions. Established business continuity plans were activated in order to mitigate the impact to our control environment, operating procedures, data and internal controls. The design of our processes and controls allow for remote execution with accessibility to secure data.
As of the end of the period covered by this quarterly report, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based upon that evaluation, management has concluded that the Company’s disclosure controls and procedures were effective as of March 31, 2020.
(b) Changes in Internal Control over Financial Reporting
There were no changes in the Company’s internal control over financial reporting during the three months ending March 31, 2020, that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
Risk factors
As filed, 10,912 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
You should carefully consider the risk factors below and previously disclosed in Part I, Item 1A “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2019.
The COVID-19 pandemic and measures taken to contain it have materially adversely affected, and are likely to continue to materially adversely affect, our business, results of operations and financial condition.
The COVID-19 pandemic has materially and adversely impacted the global economy and financial markets, with global legislative and regulatory responses including unprecedented monetary and fiscal policy actions across all sectors, and there is significant uncertainty as to timing of stabilization and recovery. Our business, results of operations and financial condition were materially adversely affected by the COVID-19 pandemic in the first quarter of 2020, especially beginning in March, and are likely to continue to be materially adversely affected, with such impact having materially worsened to date in the second quarter. The COVID-19 pandemic and measures taken to contain it have subjected our business, results of operations and financial condition to a number of material risks and uncertainties, including, but not limited to:
- Risks Related to our Liquidity. We recently borrowed $169.5 million to provide financial flexibility and have taken other significant actions to conserve cash. As of March 31, 2020, our consolidated indebtedness was $225.4 million. Our increased indebtedness will result in, among other things, increased interest expense and may increase our vulnerability to future adverse economic and industry conditions. We may incur additional significant borrowing in the near term, which would increase risks related to indebtedness. In addition, future borrowing availability under our Amended Credit Agreement is subject to our compliance with financial covenants thereunder (including the Consolidated Leverage Ratio based on consolidated EBITDA for the applicable trailing 12-month period). Based upon consolidated EBITDA for the twelve months ended March 31, 2020, $226,743 remains available for additional borrowings under the Amended Credit Agreement subject to specified conditions that Gentherm currently satisfies. We expect our consolidated EBITDA for the trailing 12-months to be significantly reduced as of the end of the second quarter 2020 due to the COVID-19 impact and it may continue to deteriorate thereafter. Therefore, subject to any amendment or waiver from lenders, we expect our borrowing availability as of the end of the second quarter, and potentially thereafter, to be materially less than the full amount of capacity available. Failure to satisfy certain covenants in the Amended Credit Agreement would result in an event of default, following which our lenders could declare all amounts outstanding to be immediately due and payable and there is no guarantee that we would be able to repay, refinance, or restructure the payments on such debt on acceptable terms or at all. Further, under the Amended Credit Agreement, the lenders would have the right to foreclose on certain of our assets, which could have a material adverse effect on our business, liquidity, results of operations and financial condition. We may finance additional liquidity needs in the future through one or more equity or debt offerings. The current disruption of the global financial markets could reduce our ability to access additional capital on acceptable terms or at all, which would negatively affect our liquidity and may adversely impact our operations and results of operations.
- Risks Related to the Automotive Industry. The automotive industry is our primary market. The COVID-19 pandemic has disrupted, and may continue to disrupt, the global automotive industry and customer sales, production volumes and purchases of light vehicles by end-consumers. Further, the spread of COVID-19 has created a disruption in the manufacturing, delivery and overall supply chain of automobile manufacturers and suppliers. In April 2020, IHS Markit forecasted light vehicle production volume for full-year 2020 of 69.3 million units, a decline of 22.0% from full-year 2019. Further, the COVID-19 pandemic has resulted in a temporary shutdown of substantially all of the major OEMs in our markets at various times in the first quarter 2020. This has significantly reduced our year-to-date sales volumes and revenue as compared to our budget, and future sales volumes and revenue remain highly uncertain. Even when automotive production resumes, customer sales and production volumes may continue to decrease or may be very volatile due to global economic impacts and uncertainties. Any prolonged reduction in actual revenues and anticipated reduction in projected revenues may require us to evaluate our intangible assets or goodwill for impairment.
- Risks Related to our Supply Chain and our Manufacturing Operations. The COVID-19 pandemic has adversely impacted our ability to manufacture products and obtain materials from our supply chain. We and our suppliers have experienced facility closures, work stoppages, travel restrictions, implementation of precautionary health and safety measures and other
restrictions. We have experienced extended work stoppages in China, and subsequent suspension of vehicle production by our OEM customers in North America and Europe, which combined accounts for greater than 75% of our annual product revenue, as the pandemic spread to those regions and governmental authorities initiated “lock-down” orders for all non-essential activities. Due to the COVID-19 pandemic, a significant portion of our employees are now working from home, while under shelter-in-place orders or other restrictions, which may harm our ability to manage our business and increase operational risk, including increased cyber security attacks and reduced ability to implement security measures. Further, companies in our global supply chain are subject to distinct legislative and regulatory requirements and limitations. Certain companies in our supply chain have had significant employee layoffs or furloughs and have significant financial distress, and some may determine to cease operations or restructure their business. When business operations begin to resume, our suppliers may not be able to manufacture the materials and products we require according to our schedule and specifications, and we may need to seek alternate suppliers, which may be more expensive or may result in delays. Further, we and our suppliers and customers also will need to modify work or production methods, enhance health and hygiene requirements for the safety of employees and incur other unanticipated expenses to protect the welfare of employees. We expect that a portion of our employees may not want to or be able return to work when permitted due to health, safety, family or otherwise. As a result, we and our supply chain may operate significantly below capacity for an uncertain period of time even after operations resume, each of which could materially adversely affect our business, results of operations and financial condition.
- Risks Related to our Customers. COVID-19 has and will continue to have a material adverse impact on the growth, viability and financial stability of our customers, including the OEMs and Tier 1 automotive suppliers to which our products are supplied. In addition to many of the risks noted above that apply to our customers regarding the automotive industry generally and our supply chain, we expect to continue to experience a delay in our collection of accounts receivable balances from our customers, which may be significant and would be at risk in the event of their bankruptcy or other restructuring.
- Risks Related to our Growth Prospects. Our ability to execute our business strategy through the pursuit of business ventures, acquisitions, and strategic alliances or dispositions has been, and will likely continue to be, materially adversely impacted by COVID-19 and global economic conditions. While we continue to believe in our long-term growth strategy and prospects, we are limiting certain growth opportunities in the near term to conserve cash, including limiting the review of merger and acquisition opportunities and certain research and development activities. We also believe that the receipt of new business awards will be more limited in the near term, and such new business awards may be subject to increased risk of future change as we look to convert awards into revenue. Further, a sustained decline in automotive production may delay or reduce our returns on research and development investments, which could materially adversely affect our business, results of operations and financial condition.
- Risks Related to Tax Matters. The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer-side social security payroll taxes, the allowance of a five-year net operating loss carryback period and the temporary suspension of the 80% net operating loss limitation, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. We currently expect to defer the payment of payroll taxes each quarter for the remainder of 2020, with such taxes to be paid in the fourth quarters of 2021 and 2022 as permitted by the CARES Act. We continue to examine the impacts the CARES Act may have on our business, but the extent to which we will benefit from the tax provisions in the CARES Act is currently unclear.
We are likely to continue to experience material adverse impacts for an uncertain period of time, even after business operations resume. The extent to which the COVID-19 pandemic materially adversely affects our business, results of operations and financial condition will depend on developments that are highly uncertain and cannot be predicted, including, but not limited to, the duration and spread of the pandemic, its severity, the effectiveness of actions to contain the virus or treat its impact and how quickly and to what extent normal economic and operating conditions can resume. At this time, we are unable to predict whether the COVID-19 pandemic will result in permanent changes to the global automotive industry and our business practices or production capabilities.
In addition to the risks specifically described above, the COVID-19 pandemic has exacerbated and precipitated the other risks described in our Annual Report on Form 10-K for the year ended December 31, 2019, and may continue to do so, in ways that we are not currently able to predict, any of which could materially adversely affect our business, results of operations, financial condition, liquidity or stock price.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2020-01-01 to 2020-03-31 | $228.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2020-01-01 to 2020-03-31 | $162.5m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2020-01-01 to 2020-03-31 | $66.1m | us-gaap:GrossProfit |
| Research and development | 3 months2020-01-01 to 2020-03-31 | $17.8m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2020-01-01 to 2020-03-31 | $25.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2020-01-01 to 2020-03-31 | $18.7m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2020-01-01 to 2020-03-31 | $5.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2020-01-01 to 2020-03-31 | $11.9m | us-gaap:ProfitLoss |
| Diluted EPS | 3 months2020-01-01 to 2020-03-31 | $0.36 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2020-01-01 to 2020-03-31 | $0.36 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2020-01-01 to 2020-03-31 | 32,869,149 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2020-01-01 to 2020-03-31 | $29.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2020-01-01 to 2020-03-31 | $3.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 3 months2020-01-01 to 2020-03-31 | $9.1m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2020-03-31 | $222.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-03-31 | $547.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2020-03-31 | $893.4m | us-gaap:Assets |
| Current liabilities | At period end2020-03-31 | $171.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-03-31 | $423.0m | us-gaap:Liabilities |
| Long-term debt | At period end2020-03-31 | $231.7m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2020-03-31 | $2.5m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2020-03-31 | $470.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001564590-20-022991. Last ingested by Listed: Oct 26, 2026, 17:44 ET. Listed shows no prices and gives no investment advice.